FI121528B - Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa - Google Patents

Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa Download PDF

Info

Publication number: FI121528B
Authority: FI; Finland
Prior art keywords: acetaldehyde; composition; cysteine; stomach; composition according
Prior art date: 2000-10-30

Application number

FI20002392A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI20002392A0 (fi

FI20002392A (fi

Inventor

Martti Lauri Antero Marvola

Mikko Salaspuro

Original Assignee

Biohit Oyj

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-30

Filing date

2000-10-30

Publication date

2010-12-31

2000-10-30 Application filed by Biohit Oyj filed Critical Biohit Oyj

2000-10-30 Publication of FI20002392A0 publication Critical patent/FI20002392A0/fi

2000-10-30 Priority to FI20002392A priority Critical patent/FI121528B/fi

2001-10-30 Priority to US10/415,422 priority patent/US9474733B2/en

2001-10-30 Priority to EA200300532A priority patent/EA009335B1/ru

2001-10-30 Priority to AU2002212395A priority patent/AU2002212395A1/en

2001-10-30 Priority to PCT/FI2001/000948 priority patent/WO2002036098A1/en

2001-10-30 Priority to CNB018216285A priority patent/CN100467016C/zh

2001-10-30 Priority to JP2002538910A priority patent/JP4691312B2/ja

2001-10-30 Priority to EP01980581A priority patent/EP1339394B1/en

2001-10-30 Priority to AT01980581T priority patent/ATE522203T1/de

2001-10-30 Priority to ES01980581T priority patent/ES2370811T3/es

2002-05-01 Publication of FI20002392A publication Critical patent/FI20002392A/fi

2007-04-09 Priority to US11/783,333 priority patent/US20080000489A1/en

2010-12-31 Application granted granted Critical

2010-12-31 Publication of FI121528B publication Critical patent/FI121528B/fi

2011-01-11 Priority to US13/004,302 priority patent/US20110171296A1/en

Links

IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 title claims abstract description 235
210000002784 stomach Anatomy 0.000 title claims abstract description 47
210000003296 saliva Anatomy 0.000 title claims abstract description 32
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
210000001072 colon Anatomy 0.000 title claims description 19
206010028980 Neoplasm Diseases 0.000 title claims description 12
201000011510 cancer Diseases 0.000 title claims description 11
150000001875 compounds Chemical class 0.000 claims abstract description 20
210000002429 large intestine Anatomy 0.000 claims abstract description 14
239000000203 mixture Substances 0.000 claims description 67
238000002360 preparation method Methods 0.000 claims description 49
239000008187 granular material Substances 0.000 claims description 30
239000011230 binding agent Substances 0.000 claims description 28
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 25
229920000642 polymer Polymers 0.000 claims description 25
239000003826 tablet Substances 0.000 claims description 25
210000000214 mouth Anatomy 0.000 claims description 15
239000000126 substance Substances 0.000 claims description 12
229920002125 Sokalan® Polymers 0.000 claims description 10
230000002496 gastric effect Effects 0.000 claims description 10
229920001661 Chitosan Polymers 0.000 claims description 9
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 9
235000019700 dicalcium phosphate Nutrition 0.000 claims description 9
239000002775 capsule Substances 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 8
239000000945 filler Substances 0.000 claims description 8
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
230000009471 action Effects 0.000 claims description 7
239000013543 active substance Substances 0.000 claims description 7
239000000843 powder Substances 0.000 claims description 7
235000010443 alginic acid Nutrition 0.000 claims description 6
229920000615 alginic acid Polymers 0.000 claims description 6
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
239000007931 coated granule Substances 0.000 claims description 5
229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
239000008108 microcrystalline cellulose Substances 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 4
208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
208000029742 colonic neoplasm Diseases 0.000 claims description 4
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 4
229920000609 methyl cellulose Polymers 0.000 claims description 4
239000001923 methylcellulose Substances 0.000 claims description 4
235000010981 methylcellulose Nutrition 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
230000002035 prolonged effect Effects 0.000 claims description 4
208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
229920000148 Polycarbophil calcium Polymers 0.000 claims description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
229960001631 carbomer Drugs 0.000 claims description 3
239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
239000011248 coating agent Substances 0.000 claims description 3
238000000576 coating method Methods 0.000 claims description 3
210000001156 gastric mucosa Anatomy 0.000 claims description 3
210000003736 gastrointestinal content Anatomy 0.000 claims description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 2
229930195710 D‐cysteine Natural products 0.000 claims description 2
ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 2
235000010980 cellulose Nutrition 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
239000004201 L-cysteine Substances 0.000 claims 11
235000013878 L-cysteine Nutrition 0.000 claims 11
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 1
229940072056 alginate Drugs 0.000 claims 1
229920001577 copolymer Polymers 0.000 claims 1
230000001934 delay Effects 0.000 claims 1
239000008202 granule composition Substances 0.000 claims 1
230000008961 swelling Effects 0.000 claims 1
125000003277 amino group Chemical group 0.000 abstract description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
235000018417 cysteine Nutrition 0.000 description 14
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 14
229960002433 cysteine Drugs 0.000 description 14
235000013334 alcoholic beverage Nutrition 0.000 description 13
238000009472 formulation Methods 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
235000013305 food Nutrition 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
210000003238 esophagus Anatomy 0.000 description 8
230000000391 smoking effect Effects 0.000 description 8
238000000034 method Methods 0.000 description 7
210000003800 pharynx Anatomy 0.000 description 7
125000003396 thiol group Chemical group [H]S* 0.000 description 7
230000000699 topical effect Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
239000004480 active ingredient Substances 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
229940078469 dl- cysteine Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
239000000499 gel Substances 0.000 description 5
235000010413 sodium alginate Nutrition 0.000 description 5
239000000661 sodium alginate Substances 0.000 description 5
229940005550 sodium alginate Drugs 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
238000013268 sustained release Methods 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000000711 cancerogenic effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
230000000813 microbial effect Effects 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
239000012049 topical pharmaceutical composition Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
229920003137 Eudragit® S polymer Polymers 0.000 description 3
230000001476 alcoholic effect Effects 0.000 description 3
231100000315 carcinogenic Toxicity 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000007888 film coating Substances 0.000 description 3
238000009501 film coating Methods 0.000 description 3
230000037406 food intake Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
239000002245 particle Substances 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
238000012360 testing method Methods 0.000 description 3
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102000004243 Tubulin Human genes 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
229960003121 arginine Drugs 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
235000013361 beverage Nutrition 0.000 description 2
201000004101 esophageal cancer Diseases 0.000 description 2
229930003935 flavonoid Natural products 0.000 description 2
150000002215 flavonoids Chemical class 0.000 description 2
235000017173 flavonoids Nutrition 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000011389 fruit/vegetable juice Nutrition 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
-1 i.e. Chemical compound 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
229960004452 methionine Drugs 0.000 description 2
230000007269 microbial metabolism Effects 0.000 description 2
210000002200 mouth mucosa Anatomy 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
201000008006 pharynx cancer Diseases 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
IAICFWDJMWEXAO-UHFFFAOYSA-N 2-(2-sulfanylethylamino)acetic acid Chemical compound OC(=O)CNCCS IAICFWDJMWEXAO-UHFFFAOYSA-N 0.000 description 1
LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical group CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
FFFHZYDWPBMWHY-UHFFFAOYSA-N HOMOCYSTEINE Chemical compound OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 description 1
206010019133 Hangover Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229940045110 chitosan Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000019987 cider Nutrition 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000015243 ice cream Nutrition 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229920000831 ionic polymer Polymers 0.000 description 1
235000020094 liqueur Nutrition 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
150000002735 metacrylic acids Chemical class 0.000 description 1
FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229940100691 oral capsule Drugs 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
235000014594 pastries Nutrition 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229950005134 polycarbophil Drugs 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000012216 screening Methods 0.000 description 1
DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
235000020046 sherry Nutrition 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
235000015096 spirit Nutrition 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
125000001174 sulfone group Chemical group 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
229960003495 thiamine Drugs 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
229960000344 thiamine hydrochloride Drugs 0.000 description 1
239000011747 thiamine hydrochloride Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
235000019505 tobacco product Nutrition 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
229960004295 valine Drugs 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000014101 wine Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nutrition Science (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Confectionery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FI20002392A 2000-10-30 2000-10-30 Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa FI121528B (fi)

Priority Applications (12)

Application Number	Priority Date	Filing Date	Title
FI20002392A FI121528B (fi)	2000-10-30	2000-10-30	Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
JP2002538910A JP4691312B2 (ja)	2000-10-30	2001-10-30	唾液、胃、大腸におけるアセトアルデヒドを結合するための方法および製剤
AT01980581T ATE522203T1 (de)	2000-10-30	2001-10-30	Pharmazeutische herstellung zur bindung von acetaldehyd in speichel, magen und dickdarm
AU2002212395A AU2002212395A1 (en)	2000-10-30	2001-10-30	Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
PCT/FI2001/000948 WO2002036098A1 (en)	2000-10-30	2001-10-30	Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
CNB018216285A CN100467016C (zh)	2000-10-30	2001-10-30	用于结合唾液、胃和大肠中乙醛的方法与制剂
US10/415,422 US9474733B2 (en)	2000-10-30	2001-10-30	Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
EP01980581A EP1339394B1 (en)	2000-10-30	2001-10-30	Pharmaceutical preparation for binding acetaldehyde in saliva, stomach and large intestine
EA200300532A EA009335B1 (ru)	2000-10-30	2001-10-30	Способ и состав для связывания ацетальдегида в слюне, желудке и толстой кишке
ES01980581T ES2370811T3 (es)	2000-10-30	2001-10-30	Preparación farmacéutica para unirse a acetaldehído en la saliva, el estómago y el intestino grueso.
US11/783,333 US20080000489A1 (en)	2000-10-30	2007-04-09	Method and preparation for binding aldehydes in saliva
US13/004,302 US20110171296A1 (en)	2000-10-30	2011-01-11	Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FI20002392A FI121528B (fi)	2000-10-30	2000-10-30	Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
FI20002392		2000-10-30

Publications (3)

Publication Number	Publication Date
FI20002392A0 FI20002392A0 (fi)	2000-10-30
FI20002392A FI20002392A (fi)	2002-05-01
FI121528B true FI121528B (fi)	2010-12-31

Family

ID=8559405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI20002392A FI121528B (fi)	2000-10-30	2000-10-30	Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa

Country Status (10)

Country	Link
US (1)	US9474733B2 (zh)
EP (1)	EP1339394B1 (zh)
JP (1)	JP4691312B2 (zh)
CN (1)	CN100467016C (zh)
AT (1)	ATE522203T1 (zh)
AU (1)	AU2002212395A1 (zh)
EA (1)	EA009335B1 (zh)
ES (1)	ES2370811T3 (zh)
FI (1)	FI121528B (zh)
WO (1)	WO2002036098A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI121528B (fi)	2000-10-30	2010-12-31	Biohit Oyj	Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
EP1343492B1 (en)	2000-11-22	2006-02-01	Rxkinetix, Inc.	Treatment of mucositis
JP5654726B2 (ja) *	2004-10-08	2015-01-14	ビオヒット・ユルキネン・オサケユキテュアＢｉｏｈｉｔＯｙｊ	唾液中のアルデヒド類を結合するための方法および製剤
ITME20040015A1 (it) *	2004-12-07	2005-03-07	Vincenzo Savica	Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
FI122914B (fi) *	2005-04-01	2012-08-31	Biohit Oyj	Elintarvikekoostumus asetaldehydin sitomiseksi suussa ja ruoansulatuskanavassa ja menetelmä koostumuksen valmistamiseksi
WO2007009012A2 (en) *	2005-07-13	2007-01-18	Al Czap	Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
AU2006320538B2 (en)	2005-11-30	2013-07-04	Endo Pharmaceuticals Inc.	Treatment of xerostomia with a sulfur-containing antioxidant
FI20060501L (fi) *	2006-05-22	2007-11-23	Biohit Oyj	Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US20100166833A1 (en) *	2007-05-07	2010-07-01	Technion Research & Development Foundation Ltd.	Compositions, articles and methods for preventing or reducing tobacco-associated damage
FI120526B (fi) *	2007-05-16	2009-11-30	Biohit Oyj	Filtteri tupakkatuotteeseen
FI20070705L (fi)	2007-09-14	2009-06-02	Biohit Oyj	Asetaldehydin sitominen suussa ja mahalaukussa
WO2009048780A1 (en) *	2007-10-08	2009-04-16	The University Of Kentucky Research Foundation	Polymer-metal chelator conjugates and uses thereof
IL188681A0 (en) *	2008-01-09	2008-12-29	Amino Acid Solutions Inc	Pharmaceutical compositions and methods utilizing a d-amino acid
FI20115680L (fi) *	2011-06-29	2012-12-30	Biohit Oyj	Nestemäisiä farmaseuttisia koostumuksia tai yhdistelmätuotteita
FI129157B (fi) *	2012-05-28	2021-08-13	Biohit Oyj	Koostumus käytettäväksi vakavien päänsärkyjen esiintymistiheyden pienentämiseksi tai niiden vähentämiseksi
FI20135097L (fi) *	2013-02-01	2014-08-02	Biohit Oyj	Koostumus aldehydien sitomiseen suussa
US20160022621A1 (en)	2013-03-12	2016-01-28	Biohit Oyj	Composition for oral administration for binding aldehydes in the gastrointestinal tract
US20160022620A1 (en)	2013-03-12	2016-01-28	Biohit Oyj	Encapsulated composition for binding aldehydes in the stomach
FI20145217A (fi)	2014-03-06	2015-09-07	Biohit Oyj	Koostumus aldehydien ja vapaiden radikaalien sitomiseksi ruoansulatuskanavassa
CN108671232A (zh) *	2018-07-09	2018-10-19	珠海中科先进技术研究院有限公司	一种能够降低体内乙醛浓度的组合制剂及其制备方法与用途
US11717554B2 (en) *	2019-09-19	2023-08-08	Max R&D Llc	Method for preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3176313D1 (en) *	1980-12-09	1987-08-20	Teijin Ltd	Novel halogenated prostacyclins, process for the production thereof, and pharmaceutical use thereof
US4496548A (en)	1983-02-04	1985-01-29	Moldowan Mervin J	Composition and method for reducing hangover
GB8313044D0 (en)	1983-05-12	1983-06-15	Caseley J R	Reducing toxic effects of tobacco
US4528295A (en) *	1983-08-15	1985-07-09	Boris Tabakoff	Composition and method for reducing blood acetaldehyde levels
JPS6116144A (ja)	1984-06-29	1986-01-24	Fujitsu Ten Ltd	異常シフト警報装置
US5202354A (en) *	1986-02-18	1993-04-13	Takeda Chemical Industries, Ltd.	Composition and method for reducing acetaldehyde toxicity
PH22818A (en)	1986-02-18	1989-01-19	Takeda Chemical Industries Ltd	Composition and method for reducing acetaldehyde toxicity
JPS62195323A (ja) *	1986-02-24	1987-08-28	Eisai Co Ltd	胃内滞留型粒子
WO1988000051A1 (en) *	1986-06-24	1988-01-14	Racz Istvan	Proceeding for the production of pharmaceutical preparations of high gastric acid binding capacity, of retarded effect and of increased bioavailability
GB2196252B (en) *	1986-09-18	1990-10-17	London Pharmacy Innovation	Gastric controlled-release dosage forms
HU201865B (en)	1989-04-28	1991-01-28	Pecsi Dohanygyar	Tobacco-smoke filter of high efficiency
JPH0374327A (ja) *	1989-08-16	1991-03-28	Ajinomoto Co Inc	アルコール代謝促進剤
JPH03136895A (ja)	1989-10-23	1991-06-11	Fuji Electric Co Ltd	光情報記録媒体の製造方法
JPH0421635A (ja)	1990-05-16	1992-01-24	Suntory Ltd	アセトアルデヒドの毒性抑制剤およびアセトアルデヒドの毒性抑制に有効な飲食物
US5110423A (en) *	1990-05-25	1992-05-05	Technic Inc.	Bath for electroplating bright tin or tin-lead alloys and method thereof
JP3013860B2 (ja)	1991-03-22	2000-02-28	三菱瓦斯化学株式会社	食品保存剤およびこれを用いた食品の保存方法
FI93924C (fi) *	1991-09-17	1995-06-26	Martti Lauri Antero Marvola	Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
US5169638A (en) *	1991-10-23	1992-12-08	E. R. Squibb & Sons, Inc.	Buoyant controlled release powder formulation
JP3479986B2 (ja) *	1992-10-07	2003-12-15	大正製薬株式会社	アルコール性肝障害予防用組成物
US5958458A (en) *	1994-06-15	1999-09-28	Dumex-Alpharma A/S	Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5695781A (en) *	1995-03-01	1997-12-09	Hallmark Pharmaceuticals, Inc.	Sustained release formulation containing three different types of polymers
JPH09194361A (ja) *	1996-01-19	1997-07-29	Wakunaga Pharmaceut Co Ltd	抗腫瘍剤
WO1998003260A1 (fr) *	1996-07-22	1998-01-29	Kouki Bussan Yugenkaisha	Nouvel adsorbant
US5829449A (en)	1997-09-19	1998-11-03	Thione International, Inc.	Smoking products containing antioxidants
IN186245B (zh) *	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
US5922346A (en) *	1997-12-01	1999-07-13	Thione International, Inc.	Antioxidant preparation
AU4398299A (en)	1999-05-24	2000-12-12	Hee Jung Kim	Composition for recovering from a hangover and for preventing brain cell damage
JP2003514020A (ja) *	1999-10-29	2003-04-15	ニトロメドインコーポレーテッド	酸化窒素不足により特徴付けられる血管疾患の治療法
FI121528B (fi)	2000-10-30	2010-12-31	Biohit Oyj	Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
ITPI20010014A1 (it)	2001-03-05	2002-09-05	Ivo Pera	Composto per filtri per sigarette,o altri articoli da fumo,a base di sostanze antiossidanti ed il filtro cosi'ottenuto
WO2002098405A1 (fr)	2001-06-05	2002-12-12	Ajinomoto Co., Inc.	Inhibiteurs de fibrose du foie
JP2003055215A (ja)	2001-06-05	2003-02-26	Ajinomoto Co Inc	肝線維化抑制剤
US6936283B2 (en) *	2003-07-25	2005-08-30	Langeland Bjoern T.	Composition for stimulation of specific metallo-enzymes
AU2005211936B2 (en)	2004-02-17	2011-06-09	Markus Graf V. Matuschka-Greiffenclau	Alcohol metabolism moderating composition

2000
- 2000-10-30 FI FI20002392A patent/FI121528B/fi not_active IP Right Cessation
2001
- 2001-10-30 JP JP2002538910A patent/JP4691312B2/ja not_active Expired - Lifetime
- 2001-10-30 US US10/415,422 patent/US9474733B2/en active Active
- 2001-10-30 WO PCT/FI2001/000948 patent/WO2002036098A1/en active Application Filing
- 2001-10-30 EA EA200300532A patent/EA009335B1/ru not_active IP Right Cessation
- 2001-10-30 ES ES01980581T patent/ES2370811T3/es not_active Expired - Lifetime
- 2001-10-30 AU AU2002212395A patent/AU2002212395A1/en not_active Abandoned
- 2001-10-30 EP EP01980581A patent/EP1339394B1/en not_active Expired - Lifetime
- 2001-10-30 CN CNB018216285A patent/CN100467016C/zh not_active Expired - Lifetime
- 2001-10-30 AT AT01980581T patent/ATE522203T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2004512353A (ja)	2004-04-22
FI20002392A0 (fi)	2000-10-30
FI20002392A (fi)	2002-05-01
EA009335B1 (ru)	2007-12-28
US9474733B2 (en)	2016-10-25
ATE522203T1 (de)	2011-09-15
JP4691312B2 (ja)	2011-06-01
ES2370811T3 (es)	2011-12-23
EP1339394A1 (en)	2003-09-03
CN100467016C (zh)	2009-03-11
CN1486177A (zh)	2004-03-31
EP1339394B1 (en)	2011-08-31
US20050267042A1 (en)	2005-12-01
AU2002212395A1 (en)	2002-05-15
EA200300532A1 (ru)	2003-10-30
WO2002036098A1 (en)	2002-05-10

Legal Events

Date	Code	Title	Description
2020-11-26	MA	Patent expired

Publication	Publication Date	Title
FI121528B (fi)	2010-12-31	Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
US8758812B2 (en)	2014-06-24	Composition for foodstuff for binding acetaldehyde
EA026651B1 (ru)	2017-05-31	Фармацевтический или пищевой состав с контролируемым высвобождением и способ его получения
JP2014122237A (ja)	2014-07-03	タバコ製品に添加するための要素及び製剤
US20070099843A1 (en)	2007-05-03	Nutritional supplement for the enhancement of the health of the liver
JP5879359B2 (ja)	2016-03-08	クエン酸及び重炭酸塩を含んでなる医薬組成物、並びにシスチン尿症を治療するためのこれらの使用
JP2001010977A (ja)	2001-01-16	経口用組成物
US20160022620A1 (en)	2016-01-28	Encapsulated composition for binding aldehydes in the stomach
US20110171296A1 (en)	2011-07-14	Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
AU2011100052A4 (en)	2011-02-17	Method and preparartion for binding acetaldehyde in the stomach
JP2016514120A (ja)	2016-05-19	胃腸管においてアルデヒドを結合するための経口投与用組成物
JPWO2003075918A1 (ja)	2005-06-30	塩酸ピルジカイニド含有錠剤（湿式）
WO2013161815A1 (ja)	2013-10-31	グルタミン酸及びアルギニン高含有錠剤